Lannett inks distribution agreement for generic Spiriva Handihaler

Lannett has entered into an exclusive U.S. commercialization agreement for generic Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals. The 10-year term of the agreement commences upon distribution of the product.

"We continue to add drug and device combination respiratory medications to our pipeline. We believe such products provide durable sales opportunities with relatively fewer competitors, due to the technical expertise, specialized manufacturing and financial commitment required to develop these products," said Lannett CEO Tim Crew. "With generic Spiriva Handihaler, our strategic relationship with Respirent now includes three inhaler products, each of which has the potential to be a meaningful contributor to our company's financial performance. The generic Spiriva Handihaler product is currently in development and tracking to ANDA submission in 2023."

Spiriva Handihaler had a market value of $1.5 billion for the 12 months ended May 2021 according to IQVIA, although actual generic market values are expected to be lower.

Spiriva Handihaler is a registered trademark of Boehringer Ingelheim.